Supplied strictly for in-vitro and laboratory research. Not for human or veterinary use. By ordering, you confirm you are a qualified researcher handling these materials per applicable regulations and safe lab practice.
This is a commonly paired secretagogue combination used in growth-hormone-axis research. CJC-1295 is studied as a growth-hormone-releasing hormone analog, while ipamorelin acts as a selective ghrelin-receptor agonist. Because the two engage different receptors that both feed into growth-hormone output, they are examined together for complementary effects on pulsatile signaling in laboratory models.
CJC-1295 was developed in the 2000s as a long-acting GHRH analog, and ipamorelin (code NNC 26-0161) was developed by Novo Nordisk in the late 1990s as a selective pentapeptide secretagogue. Combining a GHRH analog with a growth-hormone-secretagogue-receptor agonist is a long-standing experimental design for probing how two distinct inputs converge on secretory signaling.
The combination has been studied in preclinical endocrine models for parallel activity on the GHRH receptor and the growth-hormone-secretagogue receptor, with particular interest in secretory-pulse dynamics. Pairing the two lets researchers separate the contribution of each receptor while observing how they interact, since one extends the signaling window and the other drives sharper secretory pulses. As a combined preparation it serves as a convenient reference point for studies of synergistic endocrine signaling in the laboratory.
Manufactured in a controlled U.S. facility under strict compounding standards.
Every batch third-party tested with HPLC and mass spectrometry.
Orders dispatched same-day from our U.S. facility.
Reach out and get a response within minutes.
Everything you need to know about our products and processes.